Gilead Sciences, Inc. (NASDAQ:GILD) Expected to Post Earnings of $1.54 Per Share

Wall Street brokerages expect Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) to announce earnings per share of $1.55 for the current quarter, according to Zacks. Seven analysts have made estimates for Gilead Sciences’ earnings. The highest EPS estimate is $1.73 and the lowest is $1.29. Gilead Sciences reported earnings per share of $1.87 during the same quarter last year, which would suggest a negative year over year growth rate of 17.1%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Gilead Sciences will report full-year earnings of $6.55 per share for the current financial year, with EPS estimates ranging from $6.42 to $6.94. For the next year, analysts expect that the business will report earnings of $6.34 per share, with EPS estimates ranging from $4.97 to $7.30. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Gilead Sciences.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.32. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.28 billion. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.08 earnings per share.

A number of equities analysts have weighed in on the company. Bank of America lowered their price target on Gilead Sciences from $73.00 to $71.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 2nd. Oppenheimer lowered their price target on Gilead Sciences from $100.00 to $90.00 in a research report on Thursday, February 3rd. BMO Capital Markets began coverage on Gilead Sciences in a report on Tuesday, March 8th. They set a “hold” rating and a $65.00 price objective for the company. Morgan Stanley reduced their price objective on Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating for the company in a report on Tuesday, April 12th. Finally, Barclays reduced their price objective on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a report on Thursday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and a consensus price target of $73.38.

Shares of NASDAQ GILD opened at $60.31 on Tuesday. The business’s 50 day moving average price is $60.51 and its two-hundred day moving average price is $65.60. The company has a market cap of $75.62 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 0.42 and a beta of 0.38. The company has a quick ratio of 1.23, a current ratio of 1.54 and a debt-to-equity ratio of 1.74. Gilead Sciences has a twelve month low of $57.19 and a twelve month high of $74.12.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 29th. Investors of record on Wednesday, June 15th will be paid a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 4.84%. The ex-dividend date of this dividend is Tuesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 81.56%.

In related news, EVP Brett A. Pletcher sold 1,691 shares of the business’s stock in a transaction that occurred on Wednesday, February 9th. The stock was sold at an average price of $63.89, for a total value of $108,037.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 3,634 shares of the company’s stock in a transaction on Friday, March 11th. The stock was sold at an average price of $58.24, for a total value of $211,644.16. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Landmark Wealth Management LLC bought a new stake in Gilead Sciences during the first quarter worth $30,000. FSB Premier Wealth Management Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth $28,000. Joseph P. Lucia & Associates LLC acquired a new position in shares of Gilead Sciences during the first quarter worth $25,000. OLD Second National Bank of Aurora increased its holdings in shares of Gilead Sciences by 46.3% during the third quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 139 shares in the last quarter. Finally, Capital Advisors Ltd. LLC increased its holdings in shares of Gilead Sciences by 127.6% during the fourth quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 250 shares in the last quarter. Hedge funds and other institutional investors own 80.16% of the company’s stock.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.